Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlobeImmune begins phase II trial in pancreas cancer
The primary goal of the study is to compare the recurrence-free survival at 15 months in patients treated with either GI-4000 or placebo, in combination with adjuvant gemcitabine
The primary goal of the study is to compare the recurrence-free survival at 15 months in patients treated with either GI-4000 or placebo, in combination with adjuvant gemcitabine
AZD6244 is a selective MEK inhibitor that was in-licensed by AstraZeneca from Array in December 2003. AstraZeneca expects the first patient to be enrolled in this melanoma study
Cutaneous T-cell-lymphoma (CTCL), a type of non-Hodgkin’s lymphoma, is a slow-growing form of cancer in which some of the body’s white blood cells known as T-lymphocytes or T-cells
The study included in the investigational new drug application is designed to evaluate the pharmacokinetic parameters, appetite, food intake and safety of various dosing regimens of PYY nasal
This trial was designed to determine how CRx-150, an immuno-modulating agent, would affect various systemic inflammatory markers in individuals with periodontitis in both the acute and chronic phase
“This is very important data that further support Glumetza as a potential first line choice for controlling diabetes,” said Dr Bret Berner, vice president, product development and chief
Galapagos and GSK, through its recently established Center of Excellence for External Drug Discovery (CEEDD), will collaborate to deliver disease modifying drugs with clinical proof of concept to
Contrave and a companion clinical program Excalia are rationally formulated, proprietary combinations of marketed CNS products. They are based on approaches to the treatment of obesity that apply
The results are from a phase Ia trial evaluating the effect of bavituximab (formerly known as Tarvacin) on viral RNA serum titers when administered as single-dose monotherapy to
In addition, a shift in the non-inferiority margin may also be justified if the safety profile of Xyotax (paclitaxel poliglumex) is superior to comparators in terms of serious